JP2012530715A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012530715A5 JP2012530715A5 JP2012516315A JP2012516315A JP2012530715A5 JP 2012530715 A5 JP2012530715 A5 JP 2012530715A5 JP 2012516315 A JP2012516315 A JP 2012516315A JP 2012516315 A JP2012516315 A JP 2012516315A JP 2012530715 A5 JP2012530715 A5 JP 2012530715A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administration
- subject
- nucleobase sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21803109P | 2009-06-17 | 2009-06-17 | |
| US61/218,031 | 2009-06-17 | ||
| PCT/US2010/039077 WO2010148249A1 (en) | 2009-06-17 | 2010-06-17 | Compositions and methods for modulation of smn2 splicing in a subject |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015040152A Division JP6064139B2 (ja) | 2009-06-17 | 2015-03-02 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012530715A JP2012530715A (ja) | 2012-12-06 |
| JP2012530715A5 true JP2012530715A5 (enExample) | 2013-08-01 |
| JP5707396B2 JP5707396B2 (ja) | 2015-04-30 |
Family
ID=43356760
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012516315A Active JP5707396B2 (ja) | 2009-06-17 | 2010-06-17 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2015040152A Active JP6064139B2 (ja) | 2009-06-17 | 2015-03-02 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2016216200A Active JP6370860B2 (ja) | 2009-06-17 | 2016-11-04 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2018128926A Active JP6637121B2 (ja) | 2009-06-17 | 2018-07-06 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2019227997A Pending JP2020073498A (ja) | 2009-06-17 | 2019-12-18 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2021180965A Pending JP2022025131A (ja) | 2009-06-17 | 2021-11-05 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2023185174A Pending JP2024012416A (ja) | 2009-06-17 | 2023-10-30 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2025161821A Pending JP2026004402A (ja) | 2009-06-17 | 2025-09-29 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015040152A Active JP6064139B2 (ja) | 2009-06-17 | 2015-03-02 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2016216200A Active JP6370860B2 (ja) | 2009-06-17 | 2016-11-04 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2018128926A Active JP6637121B2 (ja) | 2009-06-17 | 2018-07-06 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2019227997A Pending JP2020073498A (ja) | 2009-06-17 | 2019-12-18 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2021180965A Pending JP2022025131A (ja) | 2009-06-17 | 2021-11-05 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2023185174A Pending JP2024012416A (ja) | 2009-06-17 | 2023-10-30 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2025161821A Pending JP2026004402A (ja) | 2009-06-17 | 2025-09-29 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US8980853B2 (enExample) |
| EP (4) | EP3449926B1 (enExample) |
| JP (8) | JP5707396B2 (enExample) |
| KR (9) | KR101965868B1 (enExample) |
| CN (5) | CN106983768B (enExample) |
| AU (2) | AU2010262862C1 (enExample) |
| CA (1) | CA2765396C (enExample) |
| CY (2) | CY1120807T1 (enExample) |
| DK (2) | DK3305302T3 (enExample) |
| ES (2) | ES2699827T3 (enExample) |
| HK (1) | HK1246648B (enExample) |
| HR (2) | HRP20181712T1 (enExample) |
| HU (2) | HUE046966T2 (enExample) |
| IL (2) | IL217014A (enExample) |
| LT (2) | LT3449926T (enExample) |
| MX (3) | MX2011014004A (enExample) |
| NO (1) | NO2020008I1 (enExample) |
| NZ (2) | NZ597071A (enExample) |
| PL (2) | PL3449926T3 (enExample) |
| PT (2) | PT3305302T (enExample) |
| RU (2) | RU2683772C2 (enExample) |
| SI (2) | SI3449926T1 (enExample) |
| SM (2) | SMT201800587T1 (enExample) |
| TR (1) | TR201816256T4 (enExample) |
| WO (1) | WO2010148249A1 (enExample) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1855694B1 (en) | 2005-02-09 | 2020-12-02 | Sarepta Therapeutics, Inc. | Antisense composition for treating muscle atrophy |
| EP3470072A1 (en) | 2005-06-23 | 2019-04-17 | Biogen MA Inc. | Compositions and methods for modulation of smn2 splicing |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
| ES2699827T3 (es) | 2009-06-17 | 2019-02-13 | Biogen Ma Inc | Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto |
| RU2612521C2 (ru) | 2009-07-06 | 2017-03-09 | Онтории, Инк. | Новые пролекарства нуклеиновых кислот и способы их применения |
| US8802642B2 (en) | 2010-04-28 | 2014-08-12 | Iowa State University Research Foundation, Inc. | Spinal muscular atrophy treatment via targeting SMN2 catalytic core |
| KR20200133284A (ko) | 2010-05-28 | 2020-11-26 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| TWI541024B (zh) * | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| US10017763B2 (en) | 2010-09-03 | 2018-07-10 | Sarepta Therapeutics, Inc. | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| CA2817256A1 (en) | 2010-11-12 | 2012-05-18 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| CA3092114A1 (en) | 2011-05-05 | 2012-11-08 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| EP2714037B1 (en) | 2011-05-25 | 2016-07-13 | Université Paris Descartes | Erk inhibitors for use in treating spinal muscular atrophy |
| CN103796657B (zh) | 2011-07-19 | 2017-07-11 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| WO2013068441A1 (en) | 2011-11-11 | 2013-05-16 | Santaris Pharma A/S | Compounds for the modulation of smn2 splicing |
| HK1201514A1 (en) | 2011-11-18 | 2015-09-04 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
| JP6496549B2 (ja) | 2011-11-30 | 2019-04-03 | サレプタ セラピューティクス， インコーポレイテッド | 脊髄性筋萎縮症における誘発されたエクソン包含 |
| WO2013086207A1 (en) | 2011-12-06 | 2013-06-13 | The Ohio State University | Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease |
| EP2831232A4 (en) | 2012-03-30 | 2015-11-04 | Univ Washington | METHOD FOR MODULATING TAU EXPRESSION TO REDUCE PROBLEMS AND MODIFY A NEURODEGENERATIVE SYNDROME |
| KR102213609B1 (ko) | 2012-07-13 | 2021-02-08 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| PL2872485T3 (pl) | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymetryczna grupa pomocnicza |
| WO2014110291A1 (en) * | 2013-01-09 | 2014-07-17 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of smn2 splicing in a subject |
| WO2014113540A1 (en) * | 2013-01-16 | 2014-07-24 | Iowa State University Research Foundation, Inc. | A deep intronic target for splicing correction on spinal muscular atrophy gene |
| CN105264091B (zh) | 2013-03-14 | 2020-02-28 | Ionis制药公司 | 用于调节tau表达的组合物和方法 |
| EP2983676B1 (en) * | 2013-04-12 | 2019-03-20 | The Curators of the University of Missouri | Smn2 element 1 antisense compositions and methods and uses thereof |
| TW202246503A (zh) | 2013-07-19 | 2022-12-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| EP3024936B1 (en) | 2013-07-25 | 2019-09-04 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| US10568898B2 (en) | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
| JP2016531570A (ja) | 2013-08-16 | 2016-10-13 | ラナ セラピューティクス インコーポレイテッド | ユークロマチン領域を標的とするオリゴヌクレオチド |
| EP3041958B1 (en) | 2013-09-04 | 2019-12-04 | Cold Spring Harbor Laboratory | Reducing nonsense-mediated mrna decay |
| US11236338B2 (en) | 2013-09-05 | 2022-02-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| BR112016016400A2 (pt) | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
| EP3797780B1 (en) | 2014-04-17 | 2022-09-14 | Biogen MA Inc. | Compositions and methods for modulation of smn2 splicing in a subject |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| CN104163871A (zh) * | 2014-08-12 | 2014-11-26 | 大连医科大学 | 抗肿瘤的特异性剪接因子及制备方法 |
| US10436802B2 (en) | 2014-09-12 | 2019-10-08 | Biogen Ma Inc. | Methods for treating spinal muscular atrophy |
| AU2015327836B2 (en) | 2014-10-03 | 2021-07-01 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| WO2016070060A1 (en) | 2014-10-30 | 2016-05-06 | The General Hospital Corporation | Methods for modulating atrx-dependent gene repression |
| US10517924B2 (en) | 2014-11-24 | 2019-12-31 | Northwestern University | High density lipoprotein nanoparticles for inflammation |
| WO2016149455A2 (en) | 2015-03-17 | 2016-09-22 | The General Hospital Corporation | The rna interactome of polycomb repressive complex 1 (prc1) |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| WO2016164896A2 (en) | 2015-04-10 | 2016-10-13 | Ionis Pharmaceuticals, Inc. | Modulation of smn expression |
| MA50829A (fr) | 2015-06-01 | 2018-04-11 | Sarepta Therapeutics Inc | Exclusion d'exon induite pat technologie antisens dans le collagène de type vii |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| US10905709B2 (en) * | 2015-08-28 | 2021-02-02 | Sarepta Therapeutics, Inc. | Modified antisense oligomers for exon inclusion in spinal muscular atrophy |
| CN108603230A (zh) | 2015-10-09 | 2018-09-28 | 南安普敦大学 | 基因表达的调节与蛋白质表达失调的筛选 |
| EP3858993A1 (en) | 2015-10-09 | 2021-08-04 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
| EP3377073A4 (en) | 2015-11-16 | 2019-06-26 | Ohio State Innovation Foundation | METHOD AND COMPOSITIONS FOR TREATING DISORDERS AND DISEASES WITH THE SURVIVAL MOTOR NEURON (SMN) PROTEIN |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| ES2903394T3 (es) | 2015-12-14 | 2022-04-01 | Cold Spring Harbor Laboratory | Composiciones para el tratamiento de la retinitis pigmentosa 13 |
| JP7049249B2 (ja) | 2015-12-14 | 2022-04-06 | コールド スプリング ハーバー ラボラトリー | 中枢神経系疾患の処置のための組成物および方法 |
| CA3005245A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of alagille syndrome |
| WO2017106377A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
| JP2019500345A (ja) | 2015-12-14 | 2019-01-10 | コールド スプリング ハーバー ラボラトリー | 肝臓病の処置のための組成物および方法 |
| WO2017184529A1 (en) | 2016-04-18 | 2017-10-26 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
| EP3452598A4 (en) | 2016-05-06 | 2020-04-29 | Exicure, Inc. | LIPOSOMAL SPHERICAL NUCLEIC ACID (ANS) CONSTRUCTS HAVING ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC INACTIVATION OF INTERLEUKIN 17 RECEPTOR RNA |
| BR112018075667B1 (pt) | 2016-06-14 | 2024-02-20 | Biogen Ma, Inc | Métodos para separar um oligonucleotídeo alvo de uma mistura contendo o oligonucleotídeo alvo e uma impureza relacionada com o produto |
| US11198867B2 (en) | 2016-06-16 | 2021-12-14 | Ionis Pharmaceuticals, Inc. | Combinations for the modulation of SMN expression |
| CN109689668B (zh) | 2016-06-24 | 2023-02-17 | 比奥根Ma公司 | 无加帽步骤的硫醇化寡核苷酸的合成 |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| HUE065170T2 (hu) | 2016-09-29 | 2024-05-28 | Biogen Ma Inc | Vegyületek és módszerek a TAU expresszió csökkentésére |
| CA3043768A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| PT3589730T (pt) | 2017-02-28 | 2024-02-28 | Univ Pennsylvania | Vetor de vírus adenoassociado (aav) de clado f e suas utilizações |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| EP3594346A4 (en) * | 2017-03-10 | 2020-12-16 | National Center For Child Health And Development | ANTISENS OLIGONUCLEOTIDE AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF TYPE IA GLYCOGEN STORAGE DISEASE |
| CA3060514A1 (en) | 2017-04-20 | 2018-10-25 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
| KR102547579B1 (ko) | 2017-06-19 | 2023-06-26 | 스미토모 긴조쿠 고잔 가부시키가이샤 | 근적외선 경화형 잉크 조성물과 그의 제조 방법, 근적외선 경화막 및 광조형법 |
| CA3195922A1 (en) | 2017-07-10 | 2019-01-17 | Geron Corporation | Improved process for preparing imetelstat |
| WO2019028440A1 (en) | 2017-08-04 | 2019-02-07 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICING |
| KR102318434B1 (ko) | 2017-08-25 | 2021-11-01 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| EP3694530A4 (en) * | 2017-10-12 | 2021-06-30 | Wave Life Sciences Ltd. | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
| US11555189B2 (en) | 2017-10-18 | 2023-01-17 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
| HUE070436T2 (hu) | 2017-10-23 | 2025-06-28 | Stoke Therapeutics Inc | Antiszensz oligomerek nonszensz-mediált RNS-lebomláson alapuló állapotok és betegségek kezelésére |
| WO2019094253A1 (en) | 2017-11-08 | 2019-05-16 | Avexis Inc. | Means and method for preparing viral vectors and uses of same |
| EP3737755B1 (en) * | 2018-01-12 | 2024-08-28 | Camena Bioscience Limited | Method for template-free geometric enzymatic nucleic acid synthesis |
| SG11202006528XA (en) | 2018-01-12 | 2020-08-28 | Bristol Myers Squibb Co | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| CN120310791A (zh) | 2018-01-12 | 2025-07-15 | 百时美施贵宝公司 | 靶向α-突触核蛋白的反义寡核苷酸及其用途 |
| CN119679944A (zh) | 2018-01-25 | 2025-03-25 | 渤健马萨诸塞州股份有限公司 | 治疗脊髓性肌萎缩症的方法 |
| US20210002640A1 (en) * | 2018-02-28 | 2021-01-07 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs for survival of motor neuron (sma) inhibitors |
| WO2019168558A1 (en) * | 2018-02-28 | 2019-09-06 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs for survival of motor neuron (sma) inhibitors |
| KR102398295B1 (ko) | 2018-03-09 | 2022-05-17 | 다이이찌 산쿄 가부시키가이샤 | 당원병 Ia형 치료약 |
| EP3769769A4 (en) | 2018-03-19 | 2022-05-04 | National University Corporation Tokyo Medical and Dental University | NUCLEIC ACID WITH REDUCED TOXICITY |
| CA3099280A1 (en) | 2018-05-04 | 2019-11-07 | Stoke Therapeutics, Inc. | Methods and compositions for treatment of cholesteryl ester storage disease |
| EP3801638A1 (en) | 2018-06-08 | 2021-04-14 | Novartis AG | Cell-based assay for measuring drug product potency |
| BR112020026637A2 (pt) | 2018-06-27 | 2021-03-30 | Reborna Biosciences, Inc. | Agente profilático ou terapêutico para atrofia muscular espinhal |
| US20210308281A1 (en) * | 2018-08-15 | 2021-10-07 | Biogen Ma Inc. | Combination therapy for spinal muscular atrophy |
| US20220089704A1 (en) | 2018-10-29 | 2022-03-24 | Biogen Ma Inc. | Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport |
| CN120860258A (zh) | 2018-11-30 | 2025-10-31 | 北京诺华制药有限公司 | Aav病毒载体及其用途 |
| US12429487B2 (en) | 2018-12-06 | 2025-09-30 | Biogen Ma Inc. | Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis |
| WO2020150143A2 (en) | 2019-01-14 | 2020-07-23 | Camena Bioscience Limited | Compositions and methods for template-free geometric enzymatic nucleic acid synthesis |
| EP3918069A1 (en) | 2019-01-31 | 2021-12-08 | Bar Ilan University | Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy |
| WO2020163248A1 (en) | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| CN114126613A (zh) | 2019-02-05 | 2022-03-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| EP3920915A4 (en) | 2019-02-05 | 2022-10-05 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICE |
| CN113661162A (zh) | 2019-02-06 | 2021-11-16 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| WO2020163544A1 (en) | 2019-02-06 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| AU2020227825B2 (en) | 2019-02-27 | 2026-03-26 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of conditions and diseases |
| US12595479B2 (en) | 2019-03-20 | 2026-04-07 | President And Fellows Of Harvard College | Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases |
| CA3136949A1 (en) | 2019-04-18 | 2020-10-22 | Brown University | Neurogenesis |
| CN119143828A (zh) | 2019-05-08 | 2024-12-17 | 渤健马萨诸塞州股份有限公司 | 寡核苷酸的汇聚液相合成 |
| PT3999643T (pt) | 2019-07-19 | 2023-12-11 | Biogen Ma Inc | Métodos de tratamento da atrofia muscular espinhal |
| EP4013387A4 (en) * | 2019-08-15 | 2023-09-27 | Biogen MA Inc. | COMBINATION THERAPY FOR SPINAL MUSCLE ATROPHY |
| WO2021089736A1 (en) * | 2019-11-06 | 2021-05-14 | Association Institut De Myologie | Combined therapy for muscular diseases |
| RU2738093C9 (ru) * | 2019-12-23 | 2020-12-29 | Общество с ограниченной ответственностью "Гелеспон" | Способ синтеза 2'-о-(2-метоксиэтил) тиофосфатного олигонуклеотида |
| CN120505310A (zh) * | 2020-02-28 | 2025-08-19 | Ionis制药公司 | 用于调节smn2的化合物和方法 |
| CN113444722B (zh) * | 2020-03-24 | 2024-09-24 | 中国科学院脑科学与智能技术卓越创新中心 | 单碱基编辑介导的剪接修复在制备治疗脊髓性肌萎缩症中的应用 |
| CN115867657A (zh) | 2020-05-11 | 2023-03-28 | 斯托克制药公司 | 用于治疗疾患和疾病的opa1反义寡聚物 |
| WO2022022617A1 (en) * | 2020-07-31 | 2022-02-03 | Ractigen Therapeutics | Combinatory treatment of sma with sarna and mrna modulators |
| AR125239A1 (es) | 2021-04-02 | 2023-06-28 | Kumiai Chemical Industry Co | Compuesto heterocíclico y uso del mismo |
| WO2023073526A1 (en) | 2021-10-25 | 2023-05-04 | Novartis Ag | Methods for improving adeno-associated virus (aav) delivery |
| EP4453209A1 (en) | 2021-12-20 | 2024-10-30 | Freie Universität Berlin | Methods and agents for increasing rbm3 expression |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| US20240150759A1 (en) * | 2022-11-04 | 2024-05-09 | The Board Of Trustees Of The Leland Stanford Junior University | Splicing Modulators for the Treatment of Timothy Syndrome |
| IL326390A (en) | 2023-08-10 | 2026-04-01 | Univ Pennsylvania | Compositions and methods for treating spinal muscular atrophy |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5927900A (ja) | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | 固定化オリゴヌクレオチド |
| FR2540122B1 (fr) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
| US4605735A (en) | 1983-02-14 | 1986-08-12 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives |
| US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
| US4824941A (en) | 1983-03-10 | 1989-04-25 | Julian Gordon | Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems |
| US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
| US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
| US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
| FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
| US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
| US5258506A (en) | 1984-10-16 | 1993-11-02 | Chiron Corporation | Photolabile reagents for incorporation into oligonucleotide chains |
| US4828979A (en) | 1984-11-08 | 1989-05-09 | Life Technologies, Inc. | Nucleotide analogs for nucleic acid labeling and detection |
| US4762779A (en) | 1985-06-13 | 1988-08-09 | Amgen Inc. | Compositions and methods for functionalizing nucleic acids |
| US5317098A (en) | 1986-03-17 | 1994-05-31 | Hiroaki Shizuya | Non-radioisotope tagging of fragments |
| JPS638396A (ja) | 1986-06-30 | 1988-01-14 | Wakunaga Pharmaceut Co Ltd | ポリ標識化オリゴヌクレオチド誘導体 |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
| DE3738460A1 (de) | 1987-11-12 | 1989-05-24 | Max Planck Gesellschaft | Modifizierte oligonukleotide |
| US5082830A (en) | 1988-02-26 | 1992-01-21 | Enzo Biochem, Inc. | End labeled nucleotide probe |
| US5109124A (en) | 1988-06-01 | 1992-04-28 | Biogen, Inc. | Nucleic acid probe linked to a label having a terminal cysteine |
| US5262536A (en) | 1988-09-15 | 1993-11-16 | E. I. Du Pont De Nemours And Company | Reagents for the preparation of 5'-tagged oligonucleotides |
| US5512439A (en) | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| US5599923A (en) | 1989-03-06 | 1997-02-04 | Board Of Regents, University Of Tx | Texaphyrin metal complexes having improved functionalization |
| FR2645345A1 (fr) | 1989-03-31 | 1990-10-05 | Thomson Csf | Procede de modulation dirigee de la composition ou du dopage de semi-conducteurs, notamment pour la realisation de composants electroniques monolithiques de type planar, utilisation et produits correspondants |
| US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
| US5451463A (en) | 1989-08-28 | 1995-09-19 | Clontech Laboratories, Inc. | Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides |
| US5254469A (en) | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
| US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
| DE69034150T2 (de) | 1989-10-24 | 2005-08-25 | Isis Pharmaceuticals, Inc., Carlsbad | 2'-Modifizierte Oligonukleotide |
| US5292873A (en) | 1989-11-29 | 1994-03-08 | The Research Foundation Of State University Of New York | Nucleic acids labeled with naphthoquinone probe |
| US5486603A (en) | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
| US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| US6753423B1 (en) | 1990-01-11 | 2004-06-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
| US5578718A (en) | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
| US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
| US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
| AU7579991A (en) | 1990-02-20 | 1991-09-18 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
| GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
| ES2116977T3 (es) | 1990-05-11 | 1998-08-01 | Microprobe Corp | Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente. |
| US5688941A (en) | 1990-07-27 | 1997-11-18 | Isis Pharmaceuticals, Inc. | Methods of making conjugated 4' desmethyl nucleoside analog compounds |
| US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
| US5218105A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
| US5512667A (en) | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
| KR930702373A (ko) | 1990-11-08 | 1993-09-08 | 안토니 제이. 페이네 | 합성 올리고누클레오티드에 대한 다중 리포터(Reporter)그룹의 첨합 |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US5371241A (en) | 1991-07-19 | 1994-12-06 | Pharmacia P-L Biochemicals Inc. | Fluorescein labelled phosphoramidites |
| EP0538194B1 (de) | 1991-10-17 | 1997-06-04 | Novartis AG | Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte |
| US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
| US5565552A (en) | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
| US5595726A (en) | 1992-01-21 | 1997-01-21 | Pharmacyclics, Inc. | Chromophore probe for detection of nucleic acid |
| FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
| EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
| US5272250A (en) | 1992-07-10 | 1993-12-21 | Spielvogel Bernard F | Boronated phosphoramidate compounds |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| CA2159631A1 (en) | 1993-03-30 | 1994-10-13 | Sanofi | Acyclic nucleoside analogs and oligonucleotide sequences containing them |
| DE4311944A1 (de) | 1993-04-10 | 1994-10-13 | Degussa | Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen |
| DE69435005T2 (de) | 1993-05-11 | 2008-04-17 | The University Of North Carolina At Chapel Hill | Antisense Oligonukleotide die anomales Splicing verhindern und deren Verwendung |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| DE69527439T2 (de) | 1994-02-28 | 2003-02-20 | Agritech Technologies, Ltd. | Inhibin enthaltende Zusammensetzung und ihre Verwendung |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| US5597696A (en) | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
| US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
| US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
| EP0708178A1 (en) * | 1994-10-19 | 1996-04-24 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Survival motor neuron (SMN) gene: a gene for spinal muscular atrophy |
| US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
| US7034009B2 (en) | 1995-10-26 | 2006-04-25 | Sirna Therapeutics, Inc. | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
| WO1997026270A2 (en) | 1996-01-16 | 1997-07-24 | Ribozyme Pharmaceuticals, Inc. | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
| US6214986B1 (en) | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
| US6172216B1 (en) | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
| US7053207B2 (en) | 1999-05-04 | 2006-05-30 | Exiqon A/S | L-ribo-LNA analogues |
| US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
| US6649411B2 (en) | 1999-07-30 | 2003-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of inhibiting cancer cells with ADNF III antisense oligonucleotides |
| US6770633B1 (en) | 1999-10-26 | 2004-08-03 | Immusol, Inc. | Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| US20050020525A1 (en) | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US6962906B2 (en) | 2000-03-14 | 2005-11-08 | Active Motif | Oligonucleotide analogues, methods of synthesis and methods of use |
| WO2001085751A1 (en) | 2000-05-09 | 2001-11-15 | Reliable Biopharmaceutical, Inc. | Polymeric compounds useful as prodrugs |
| CA2437942C (en) | 2000-11-09 | 2013-06-11 | Cold Spring Harbor Laboratory | Chimeric molecules to modulate gene expression |
| US6376508B1 (en) | 2000-12-13 | 2002-04-23 | Academia Sinica | Treatments for spinal muscular atrophy |
| CA2452458A1 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| GB0219143D0 (en) | 2002-08-16 | 2002-09-25 | Univ Leicester | Modified tailed oligonucleotides |
| WO2004041889A2 (en) | 2002-11-05 | 2004-05-21 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| AU2003295600A1 (en) | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| JP2004344072A (ja) * | 2003-05-22 | 2004-12-09 | Japan Science & Technology Agency | Ｓｍｎ遺伝子のスプライシング調節エレメント |
| WO2004113867A2 (en) | 2003-06-16 | 2004-12-29 | University Of Massachusetts | Exon analysis |
| EP1661905B9 (en) | 2003-08-28 | 2012-12-19 | IMANISHI, Takeshi | Novel artificial nucleic acids of n-o bond crosslinkage type |
| US20050074801A1 (en) | 2003-09-09 | 2005-04-07 | Monia Brett P. | Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry |
| CA2538252C (en) | 2003-09-18 | 2014-02-25 | Isis Pharmaceuticals, Inc. | 4'-thionucleosides and oligomeric compounds |
| GB0425625D0 (en) * | 2004-11-22 | 2004-12-22 | Royal College Of Surgeons Ie | Treatment of disease |
| US7838657B2 (en) | 2004-12-03 | 2010-11-23 | University Of Massachusetts | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
| US7879992B2 (en) | 2005-01-31 | 2011-02-01 | Isis Pharmaceuticals, Inc. | Modification of MyD88 splicing using modified oligonucleotides |
| EP3470072A1 (en) | 2005-06-23 | 2019-04-17 | Biogen MA Inc. | Compositions and methods for modulation of smn2 splicing |
| JP4223027B2 (ja) | 2005-06-30 | 2009-02-12 | シャープ株式会社 | 画像形成装置及び秘匿データ送信方法 |
| WO2007047913A2 (en) | 2005-10-20 | 2007-04-26 | Isis Pharmaceuticals, Inc | Compositions and methods for modulation of lmna expression |
| WO2007058894A2 (en) | 2005-11-10 | 2007-05-24 | The University Of North Carolina At Chapel Hill | Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease |
| EP1991677A2 (en) * | 2006-01-26 | 2008-11-19 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to huntingtin |
| AU2007211082B2 (en) | 2006-01-27 | 2012-09-27 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
| WO2007090071A2 (en) | 2006-01-27 | 2007-08-09 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
| WO2008101157A1 (en) | 2007-02-15 | 2008-08-21 | Isis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
| CA2688321A1 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| WO2009120700A2 (en) | 2008-03-26 | 2009-10-01 | Families Of Spinal Muscular Atrophy | Inhibition of dcps |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| US9156037B2 (en) | 2009-01-15 | 2015-10-13 | Children's Medical Center Corporation | Microfluidic device and uses thereof |
| US20120021515A1 (en) | 2009-02-06 | 2012-01-26 | Swayze Eric E | Oligomeric compounds and methods |
| WO2010120820A1 (en) | 2009-04-13 | 2010-10-21 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of smn2 splicing |
| ES2699827T3 (es) * | 2009-06-17 | 2019-02-13 | Biogen Ma Inc | Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto |
| WO2011032109A1 (en) | 2009-09-11 | 2011-03-17 | Sma Foundation | Biomarkers for spinal muscular atrophy |
| US8183002B2 (en) | 2009-12-03 | 2012-05-22 | Abbott Laboratories | Autoantibody enhanced immunoassays and kits |
| US10653713B2 (en) | 2010-10-06 | 2020-05-19 | Medtronic, Inc. | Methods for distributing agents to areas of brain |
| KR20140072019A (ko) | 2011-07-13 | 2014-06-12 | 머크 샤프 앤드 돔 코포레이션 | 체액 샘플에서의 아밀로이드 베타 올리고머의 검출 방법 및 그의 용도 |
| WO2014110291A1 (en) | 2013-01-09 | 2014-07-17 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of smn2 splicing in a subject |
| US20140367278A1 (en) | 2013-06-12 | 2014-12-18 | PharmOptima, LLC | Methods for Detecting Survival Motor Neuron (SMN) Protein in Whole Blood or Cerebral Spinal Fluid |
-
2010
- 2010-06-17 ES ES17203913T patent/ES2699827T3/es active Active
- 2010-06-17 AU AU2010262862A patent/AU2010262862C1/en active Active
- 2010-06-17 LT LTEP18185820.0T patent/LT3449926T/lt unknown
- 2010-06-17 SI SI201031946T patent/SI3449926T1/sl unknown
- 2010-06-17 KR KR1020197003809A patent/KR101965868B1/ko active Active
- 2010-06-17 KR KR1020207012412A patent/KR20200047790A/ko not_active Ceased
- 2010-06-17 CN CN201710003678.9A patent/CN106983768B/zh active Active
- 2010-06-17 KR KR1020267002500A patent/KR20260021813A/ko active Pending
- 2010-06-17 PL PL18185820T patent/PL3449926T3/pl unknown
- 2010-06-17 CN CN2010800368070A patent/CN102665731A/zh active Pending
- 2010-06-17 PT PT17203913T patent/PT3305302T/pt unknown
- 2010-06-17 EP EP18185820.0A patent/EP3449926B1/en active Active
- 2010-06-17 RU RU2015139553A patent/RU2683772C2/ru active
- 2010-06-17 EP EP10790221.5A patent/EP2442816A4/en not_active Withdrawn
- 2010-06-17 NZ NZ597071A patent/NZ597071A/en unknown
- 2010-06-17 NZ NZ624712A patent/NZ624712A/en unknown
- 2010-06-17 KR KR1020217014192A patent/KR20210057223A/ko not_active Ceased
- 2010-06-17 HU HUE18185820A patent/HUE046966T2/hu unknown
- 2010-06-17 MX MX2011014004A patent/MX2011014004A/es active IP Right Grant
- 2010-06-17 LT LTEP17203913.3T patent/LT3305302T/lt unknown
- 2010-06-17 WO PCT/US2010/039077 patent/WO2010148249A1/en not_active Ceased
- 2010-06-17 ES ES18185820T patent/ES2761614T3/es active Active
- 2010-06-17 US US13/380,021 patent/US8980853B2/en active Active
- 2010-06-17 EP EP17203913.3A patent/EP3305302B1/en active Active
- 2010-06-17 HU HUE17203913A patent/HUE039741T2/hu unknown
- 2010-06-17 KR KR1020247007557A patent/KR20240036132A/ko not_active Ceased
- 2010-06-17 CA CA2765396A patent/CA2765396C/en active Active
- 2010-06-17 DK DK17203913.3T patent/DK3305302T3/en active
- 2010-06-17 CN CN202210541466.7A patent/CN115227710A/zh active Pending
- 2010-06-17 PL PL17203913T patent/PL3305302T3/pl unknown
- 2010-06-17 KR KR1020127001244A patent/KR20120093138A/ko not_active Ceased
- 2010-06-17 TR TR2018/16256T patent/TR201816256T4/tr unknown
- 2010-06-17 SI SI201031784T patent/SI3305302T1/sl unknown
- 2010-06-17 JP JP2012516315A patent/JP5707396B2/ja active Active
- 2010-06-17 PT PT181858200T patent/PT3449926T/pt unknown
- 2010-06-17 MX MX2015008433A patent/MX361732B/es unknown
- 2010-06-17 DK DK18185820T patent/DK3449926T3/da active
- 2010-06-17 KR KR1020227019810A patent/KR20220084437A/ko not_active Ceased
- 2010-06-17 RU RU2012101491A patent/RU2566724C9/ru active
- 2010-06-17 SM SM20180587T patent/SMT201800587T1/it unknown
- 2010-06-17 CN CN202210540428.XA patent/CN115227709A/zh active Pending
- 2010-06-17 KR KR1020197009268A patent/KR20190037378A/ko not_active Ceased
- 2010-06-17 KR KR1020177011876A patent/KR20170054537A/ko not_active Withdrawn
- 2010-06-17 CN CN202310217516.0A patent/CN116440150A/zh active Pending
- 2010-06-17 EP EP19201392.8A patent/EP3643783A1/en active Pending
- 2010-06-17 SM SM20200020T patent/SMT202000020T1/it unknown
-
2011
- 2011-12-15 IL IL217014A patent/IL217014A/en active Protection Beyond IP Right Term
- 2011-12-16 MX MX2018015635A patent/MX2018015635A/es unknown
-
2015
- 2015-02-09 US US14/617,388 patent/US9717750B2/en active Active
- 2015-03-02 JP JP2015040152A patent/JP6064139B2/ja active Active
-
2016
- 2016-01-21 AU AU2016200344A patent/AU2016200344B2/en active Active
- 2016-04-13 IL IL245096A patent/IL245096B/en active Protection Beyond IP Right Term
- 2016-11-04 JP JP2016216200A patent/JP6370860B2/ja active Active
-
2018
- 2018-02-09 US US15/892,560 patent/US20190030058A1/en not_active Abandoned
- 2018-05-10 HK HK18106100.4A patent/HK1246648B/en unknown
- 2018-07-06 JP JP2018128926A patent/JP6637121B2/ja active Active
- 2018-10-19 HR HRP20181712TT patent/HRP20181712T1/hr unknown
- 2018-11-01 CY CY181101134T patent/CY1120807T1/el unknown
-
2019
- 2019-10-31 HR HRP20191978TT patent/HRP20191978T1/hr unknown
- 2019-12-10 US US16/708,739 patent/US20200376018A1/en not_active Abandoned
- 2019-12-18 JP JP2019227997A patent/JP2020073498A/ja active Pending
- 2019-12-19 CY CY20191101339T patent/CY1122687T1/el unknown
-
2020
- 2020-04-01 NO NO2020008C patent/NO2020008I1/no unknown
-
2021
- 2021-11-05 JP JP2021180965A patent/JP2022025131A/ja active Pending
-
2023
- 2023-10-25 US US18/494,445 patent/US20240238326A1/en not_active Abandoned
- 2023-10-30 JP JP2023185174A patent/JP2024012416A/ja active Pending
-
2025
- 2025-09-29 JP JP2025161821A patent/JP2026004402A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012530715A5 (enExample) | ||
| RU2015139553A (ru) | Композиции и способы модуляции smn2 сплайсинга у субъекта | |
| US12049627B2 (en) | Two-tailed self-delivering siRNA | |
| HRP20160261T1 (hr) | Komplementarni antagonisti i njihova uporaba | |
| JP2021513861A (ja) | Ｃａｍｋ２ｄアンチセンスオリゴヌクレオチドおよびその使用 | |
| SI2929031T1 (en) | PCSK9 IRNA assemblies and procedures for their use | |
| JP7291418B2 (ja) | Ｐｃｓｋ９を標的としたアンチセンス核酸 | |
| JP2012050438A5 (enExample) | ||
| US20180161357A1 (en) | Mir-155 inhibitors for treating amyotrophic lateral sclerosis (als) | |
| JP2016506240A5 (enExample) | ||
| US9061068B2 (en) | Polymeric nano-particles for siRNA delivery using charge interaction and covalent bonding | |
| JP2011528333A5 (enExample) | ||
| US9481887B2 (en) | DNA aptamers for promoting remyelination | |
| HRP20200117T1 (hr) | Nukleinske kiseline koje se vežu na sdf-1 i njihova upotreba | |
| JP2017509690A5 (enExample) | ||
| US20250188466A1 (en) | Methods and Compositions for Treatment of Polycystic Kidney Disease | |
| US20190071670A1 (en) | Methods Of Treatment For Alpha-1 Antitrypsin Deficiency | |
| WO2019181946A1 (ja) | 毒性が軽減した核酸 | |
| JP2016501528A5 (enExample) | ||
| KR20180080181A (ko) | 다낭포성 신장 질환의 치료 방법 | |
| KR20240101580A (ko) | Hbv 치료를 위한 약학 조합물 | |
| JP2011525531A5 (enExample) | ||
| JP2023526328A5 (enExample) | ||
| US20220056443A1 (en) | Metabolic benefits of short mir-22 mirna antagomir therapies | |
| US20240309383A1 (en) | Small interfering rna targeting hbv and uses thereof |